NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1323 to 1347 of 1403

Display Results as:

The Health of Sexual and Gender Minority (SGM) Populations (R15) - PA-15-260

Organization: NICHD 

Posting Date: 05-18-2015 

Expiration Date: 01-25-2018 

Activity Code: R15 

Summary: The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed. 

The Health of Sexual and Gender Minority (SGM) Populations (R21 Clinical Trial Optional) - PA-18-040

Organization: NICHD 

Posting Date: 11-06-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.  

The Health of Sexual and Gender Minority (SGM) Populations (R21) - PA-15-263

Organization: NICHD 

Posting Date: 05-18-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.  

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01) - PA-17-440

Organization: NCI 

Posting Date: 08-04-2017 

Expiration Date: 09-08-2020 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death. 

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) - PA-17-449

Organization: NCI 

Posting Date: 08-04-2017 

Expiration Date: 09-08-2020 

Activity Code: R21 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death. 

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) - RFA-CA-18-001

Organization: NCI 

Posting Date: 11-14-2017 

Expiration Date: 02-22-2018 

Activity Code: F99/K00 

Summary: The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. 

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) - PAR-18-467

Organization: NCI 

Posting Date: 12-06-2017 

Expiration Date: 03-13-2021 

Activity Code: K22 

Summary: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. 

The NCI Transition Career Development Award (K22 Independent Clinical Trial Required) - PAR-18-466

Organization: NCI 

Posting Date: 12-06-2017 

Expiration Date: 03-13-2021 

Activity Code: K22 

Summary: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. 

The National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS) (U24) - PAR-16-205

Organization: NIA 

Posting Date: 04-19-2016 

Expiration Date: 09-08-2019 

Activity Code: U24 

Summary: This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure to support the Alzheimer's Disease Sequencing Project (ADSP) related to the collection, longitudinal follow-up, ascertainment of antecedent risk factors, and the characterization of additional relatives from families multiply affected with Alzheimer's disease (AD) in order to expand the existing NIA Late Onset of AD Family Based Study sample set. 

The Role of Mobile Genetic Elements in Cancer (R01) - PAR-16-227

Organization: NCI 

Posting Date: 05-05-2016 

Expiration Date: 09-08-2019 

Activity Code: R01 

Summary: The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy. 

The Role of Mobile Genetic Elements in Cancer (R21) - PAR-16-226

Organization: NCI 

Posting Date: 05-05-2016 

Expiration Date: 09-08-2019 

Activity Code: R21 

Summary: The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research proposals that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.  

The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R01 - Clinical Trial Optional) - RFA-HD-19-013

Organization: NICHD 

Posting Date: 12-08-2017 

Expiration Date: 03-31-2018 

Activity Code: R01 

Summary: The purpose of the Funding Opportunity Announcement (FOA) is to encourage research into the role of pluripotent progenitor/stem cells in the pathogenesis and treatment of selected gynecologic disorders, specifically uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. 

The Role of the Microbiome in the Developmental Origins of Health and Disease (DOHaD) (R01 Clinical Trial Not Allowed) - RFA-ES-18-005

Organization: NIEHS 

Posting Date: 11-21-2017 

Expiration Date: 03-15-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) seeks innovative research proposals that use animal models to investigate the potential role of the microbiome in mediating the latent effects of early life exposure. 

The Use of mRNA for an HIV Envelope Vaccine (R41/R42) - PA-16-208

Organization: NIAID 

Posting Date: 04-19-2016 

Expiration Date: 04-06-2019 

Activity Code: R41/R42 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Technology Transfer (STTR) grant applications from Small Business Concerns (SBCs) and non-profit research institutions including academic partners that will focus on the development of novel direct mRNA-based and self-amplifying mRNA-based HIV envelope vaccine platforms suitable for use in clinical research. Such technologies should have commercial potential.  

The Use of mRNA for an HIV Envelope Vaccine (R43/R44) - PA-16-207

Organization: NIAID 

Posting Date: 04-19-2016 

Expiration Date: 04-06-2019 

Activity Code: R43/R44 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) that will focus on the development of novel direct mRNA-based and self-amplifying mRNA-based HIV envelope vaccine platforms suitable for use in clinical research. Such technologies should have commercial potential.  

Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01) - PA-17-283

Organization: NIAID 

Posting Date: 05-12-2017 

Expiration Date: 09-08-2020 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.  

Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) - PA-17-282

Organization: NIAID 

Posting Date: 05-12-2017 

Expiration Date: 09-08-2020 

Activity Code: R21 

Summary: The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.  

Time-Sensitive Obesity Policy and Program Evaluation (R01) - PAR-15-346

Organization: NIDDK 

Posting Date: 09-17-2015 

Expiration Date: 09-14-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity.This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.  

Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed) - RFA-RM-17-027

Organization: OSC 

Posting Date: 12-18-2017 

Expiration Date: 03-03-2018 

Activity Code: U54 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, multi-parameter maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with micron resolution. 

Tobacco Regulatory Science (R01 Clinical Trial Optional) - RFA-OD-18-002

Organization: NIH 

Posting Date: 11-20-2017 

Expiration Date: 02-14-2019 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. 

Tobacco Regulatory Science (R21 Clinical Trial Optional) - RFA-OD-18-003

Organization: NIH 

Posting Date: 11-20-2017 

Expiration Date: 02-14-2019 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) - RFA-OD-18-001

Organization: NIH 

Posting Date: 11-20-2017 

Expiration Date: 02-14-2019 

Activity Code: R03 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applicants are encouraged to conduct projects that ultimately have potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science. Research findings generated from this FOA are expected to provide sufficient preliminary data for subsequent investigator-initiated research that is relevant to the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. The NIH and the FDA have formed an interagency partnership to foster research relevant to tobacco regulatory science within the framework of the FSPTCA. 

Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional) - PAR-18-023

Organization: NCI 

Posting Date: 11-28-2017 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.  

Tobacco Use and HIV in Low and Middle Income Countries (R01) - PAR-17-087

Organization: NCI 

Posting Date: 12-15-2016 

Expiration Date: 01-25-2018 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.  

Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional) - PAR-18-022

Organization: NCI 

Posting Date: 11-28-2017 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top